Norman Fields Q2 2026 Investment Activity: Major Buys and Minor Adjustments

Norman Fields' portfolio saw significant changes in Q2 2026 with notable purchases of SLB Limited (SLB) and ARS Pharmaceuticals Inc. (SPRY), alongside minor adjustments to existing holdings.

By Insiderset.Jul 10, 2026, 10:17 AM
Norman Fields Q2 2026 Investment Activity: Major Buys and Minor Adjustments

Norman Fields, through his investment vehicle Gottscho Capital Management, LLC, has made several noteworthy moves during the second quarter of 2026 as reported in filings available on InsiderSet. The most significant action appears to be a substantial purchase position.

Fields significantly increased his stake in SLB Limited (SLB), commonly known as Schlumberger. According to the filing, this investment saw an increase of 9685 shares and a corresponding value growth of $766k during Q2, representing a staggering +142.43% change in just one quarter. This suggests strong confidence or alignment with SLB's recent performance or outlook.

Another major purchase was made in ARS Pharmaceuticals Inc. (SPRY). The data shows Fields added 31,230 shares during the period, pushing SPRY's allocation up by +78.37% and its total stock value to $569k. This is a highly concentrated investment increase.

Conversely, while not large-scale sales, there were notable decreases in weight for some of Fields' top holdings during Q2. Berkshire Hathaway B (BRK-B), despite being a cornerstone holding at 14.62% allocation, saw its share count decrease by -1971 shares (-2.0%) from the previous quarter.

Similarly, Liberty Media Corp - Formula O (FWONK) experienced a slight reduction in weight due to a -3,810 share change (-3.81%), and Micron Technology Inc. (MU) also saw its position decrease by -2.96% (-368 shares). These adjustments are relatively minor compared to the overall portfolio.

Other holdings like American Express Company (AXP), Union Pacific Corp (UNP), Packaging Corp of America (PKG), and On Holdings (ONON) remained unchanged in terms of share count during Q2, maintaining their respective allocations. The investor also slightly trimmed his position in Cava Group Inc. (CAVA) by -1080 shares (-3.26%) but kept the stake substantial at $269k.

Overall, Norman Fields' investment strategy for Q2 2026 involved targeted buying activities, particularly highlighted by the significant increases in SLB and SPRY, alongside minor reductions or stability in other major positions like BRK-B. For a detailed look at his portfolio holdings, visit InsiderSet.